RA INTERNATIONAL GRP. ORD 10P overview

...

SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China. The China bridge clinical trial of the Product’s RA indication reached...

RA Holding Corp. Announces Approval of Partial Redemption of Class A Preferred Shares PR Newswire NEW YORK, Nov. 6, 2023 NEW YORK , Nov. 6, 2023 /PRNewswire/ -- RA Holding Corp. ("RA Holding" or the "Company") announced today that it has approved a partial redemption of its Class A Preferred Shares issued pursuant to the Second Amended Joint Plan of Reorganization of Arcapita Bank B.S.C.(c) in the amount of $20 million or 4.3% of the total Class A Preferred Shares outstanding. The redemption...

Name change to Catheter Precision, Inc. is effective on August 17, 2023, with trading under new ticker symbol VTAK to begin on August 18, 2023 FORT MILL, SC / ACCESSWIRE / August 17, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is today, August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and...

MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug Application (IND) to evaluate the safety, efficacy, pharmacodynamics and pharmacokinetics of oral TNF-α inhibitor MYMD-1 ® in patients with active...

First patent out of six applications on file for LockeT product FORT MILL, SC / ACCESSWIRE / August 14, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) today announced that it has received notification of allowance of the first patent to be issued for the company's LockeT product. Entitled "Vessel Closing Device", the patent to be granted is one in a family of six patent applications on file in the US, and in a number of foreign countries, including the European Community, Japan, and China....

Catheter Precision's VIVO System Has Been Utilized in over 1,000 Procedures FORT MILL, SC / ACCESSWIRE / August 7, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced today that VIVO, the lead product for the electrophysiology division, has been used in more than 1000 ventricular ablation procedures. VIVO, which stands for View Into Ventricular Onset, enables physicians to learn more about patient specific anatomy and better help them plan the ablation procedure. As a result, VIVO...

Name change to Catheter Precision, Inc. expected to become effective on August 17, 2023, with trading under new ticker symbol VTAK expected to begin on August 18, 2023 FORT MILL, SC / ACCESSWIRE / July 31, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) today announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is expected to be August 17, 2023. The Company has reserved the ticker symbol...